Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)-Reference-Cited by-同舟云学术

Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)

Published:2018-01-09 Issue:7 Volume:124 Page:1449-1454
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Montemurro Michael¹^ORCID,Cioffi Angela²,Dômont Julien²,Rutkowski Piotr³,Roth Arnaud D.⁴,von Moos Roger⁵,Inauen Roman⁶,Toulmonde Maud⁷^ORCID,Burkhard Roger O.⁸,Knuesli Claudio⁹,Bauer Sebastian¹⁰,Cassier Philippe¹¹,Schwarb Heike¹²,Le Cesne Axel²,Koeberle Dieter¹³,Bärtschi Daniela¹⁴,Dietrich Daniel¹⁴,Biaggi Christine¹⁴,Prior John¹⁵^ORCID,Leyvraz Serge¹

Affiliation:

1. Medical Oncology; University Hospital of Lausanne; Lausanne Switzerland

2. Medical Oncology-Sarcoma; Gustave Roussy Institute; Villejuif France

3. Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology; Warsaw Poland

4. Division of Oncology; Geneva University Hospital; Geneva Switzerland

5. Medical Oncology and Hematology; Cantonal Hospital Graubunden; Chur Switzerland

6. Department of Oncology; Cantonal Hospital St. Gallen; St. Gallen Switzerland

7. Medical Oncology; Bergonie Institute; Bordeaux France

8. Oncology Center; Hirslanden Hospital and Health Care; Zurich Switzerland

9. Medical Oncology; Hospital St. Claraspital; Basel Switzerland

10. Department of Medical Oncology, Sarcoma Center, West German Cancer Center; University of Duisburg-Essen; Essen Germany

11. Oncology; Leon Berard Center; Lyon France

12. Oncology/Internal Medicine; Cantonal Hospital Baden; Baden Switzerland

13. Department of Oncology/Hematology; Cantonal Hospital St. Gallen; St. Gallen Switzerland

14. Coordinating Center; Swiss Group for Clinical Cancer Research; Bern Switzerland

15. Nuclear Medicine and Molecular Imaging; University Hospital of Lausanne; Lausanne Switzerland

Funder

Swiss Group for Clinical Cancer Research (SAKK)

Bristol Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference35 articles.

1. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib;Montemurro;Curr Opin Oncol.,2011

2. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study;Glabbeke;J Clin Oncol.,2005

3. Comparison of 2 doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients;Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST);J Clin Oncol.,2010

4. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors;Demetri;J Clin Oncol.,2009

5. Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study;Call;J Gastrointest Cancer.,2010

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling IL6R and MYC as Targeting Biomarkers in Imatinib-Resistant Chronic Myeloid Leukemia through Advanced Non-Invasive Apoptosis Detection Sensor Version 2 Detection;Cells;2024-04-02

2. Gastrointestinal Stromal Tumours;Tata Memorial Centre Textbook of Oncology;2024

3. Molecular pathology of gastrointestinal stromal tumors;Diagnostic Molecular Pathology;2024

4. Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia;Cancers;2023-08-20

5. Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours;Cancers;2023-08-13